# Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars

> **NCT05196373** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sirnaomics** · enrollment: 50 (estimated)

## Conditions studied

- Hypertrophic Scar

## Interventions

- **DRUG:** STP705

## Key facts

- **NCT ID:** NCT05196373
- **Lead sponsor:** Sirnaomics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05196373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05196373, "Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05196373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*